Quality control of biotechnology-derived vaccines: technical and regulatory considerations.
Vaccines for human use have been produced for decades using classical manufacturing methods including culture of viruses and bacteria followed by various concentration-, inactivation-, detoxification-, conjugation production processes. Availability of techniques for molecular biology and for the complete chemical synthesis of genes provides prospects of genetic engineering of microorganisms so as to generate novel biotechnological/biological-derived vaccines. The potential large-scale availability of biotechnology-derived vaccines makes feasible their evaluation in the prevention and/or treatment of various infectious, chronic, degenerative and cancer human diseases. There are potential safety concerns that arise from the novel manufacturing processes and from the complex structural and biological characteristics of the products. These products have distinguishing characteristics to which consideration should be given in a well-defined quality control testing programme. The evaluation of their quality, safety, efficacy and stability necessitate complex analytical methods and appropriate physicochemical, biochemical and immunochemical methods for the analysis of the molecular entity. A flexible approach to the control of these novel products is being developed by regulatory authorities so that recommendations can be modified in the light of experience of research and development in vaccinology, production and use of biotechnology products and with the further development of new technologies.
Fuchs
Florence
F
Agence Française de Sécurité Sanitaire des Produits de Santé, Site de Lyon, 321, avenue Jean-Jaurès, France. Florence.FUCHS@afssaps.sante.fr
D001709:Biotechnology / Q000331:legislation & jurisprudence / Q000592:standards*; D002986:Clinical Trials as Topic / Q000592:standards; D006801:Humans; D011786:Quality Control; D014614:Vaccines, Synthetic / Q000592:standards*
D014614:Vaccines, Synthetic